WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.
Chemoprotective agents reduce the toxic side effects of chemotherapy agents such as cisplatin. The conventional belief is that the chemoprotective agent WR-2721 (Amifostine), while protecting against most cisplatin-induced side effects, does not protect against cisplatin-induced ototoxicity (i.e., hearing loss). There is no knowledge, however, about the efficacy of high doses of WR-2721 (WR) in possibly protecting against cisplatin-induced ototoxicity. Thus, the dose-dependent effects of WR in possibly ameliorating cisplatin-induced ototoxicity were investigated. Hamsters were given a series of 5 cisplatin injections (3 mg/kg/injection once every other day, i.p.) either alone or in combination with 18, 40, 80, or 400 mg/kg/injection of the rescue agent WR ( n = 5 or 10/group). Other groups received either 80 mg/kg/injection WR alone ( n = 5) or were untreated ( n = 14). Ototoxicity was assessed by auditory brain stem responses (ABR). WR provided dose-dependent rescue from cisplatin's ototoxicity with no protection at the low dose of 18 mg/kg, moderate protection at 40 mg/kg, and nearly complete protection at 80 and 400 mg/kg. However, WR doses of 40 mg/kg or higher caused neurotoxicity as evidenced by prolongations in the ABR's interpeak latencies. Thus, high doses of WR provided the beneficial effect of protecting against cisplatin-induced ototoxicity, but had the harmful side effect of neurotoxicity. Previous failures to find chemoprotection from cisplatin-induced ototoxicity were likely due to the use of WR doses that were too small. The clinical implications of the beneficial and harmful effects of high doses of WR are discussed.
Church
Michael W
MW
Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI 48201, USA, mchurch@med.wayne.edu
Blakley
Brian W
BW
Burgio
Don L
DL
Gupta
Anil K
AK
D004999:Amifostine / Q000633:toxicity*; D000818:Animals; D001309:Auditory Threshold / Q000187:drug effects; D002945:Cisplatin / Q000633:toxicity*; D003051:Cochlea / Q000187:drug effects; D006224:Cricetinae; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005072:Evoked Potentials, Auditory / Q000187:drug effects; D034381:Hearing Loss / Q000139:chemically induced* / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008647:Mesocricetus; D011837:Radiation-Protective Agents / Q000633:toxicity*; D011838:Radiation-Sensitizing Agents / Q000633:toxicity*; D011930:Reaction Time / Q000187:drug effects
D011837:Radiation-Protective Agents; D011838:Radiation-Sensitizing Agents; D004999:Amifostine; D002945:Cisplatin